"Amides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed)
Descriptor ID |
D000577
|
MeSH Number(s) |
D02.065
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Amides".
Below are MeSH descriptors whose meaning is more specific than "Amides".
This graph shows the total number of publications written about "Amides" by people in this website by year, and whether "Amides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
2011 | 3 | 0 | 3 |
2013 | 1 | 0 | 1 |
2016 | 1 | 1 | 2 |
2017 | 13 | 18 | 31 |
2018 | 11 | 12 | 23 |
2019 | 2 | 7 | 9 |
2020 | 26 | 21 | 47 |
2021 | 22 | 14 | 36 |
To return to the timeline, click here.
Below are the most recent publications written about "Amides" by people in Profiles.
-
Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV. Mini Rev Med Chem. 2022; 22(2):232-247.
-
Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients Turk J Med Sci. 2021 12 13; 51(6):2835-2849.
-
Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19 Turk J Med Sci. 2021 12 13; 51(6):2827-2834.
-
New Pyrazine Conjugates: Synthesis, Computational Studies, and Antiviral Properties against SARS-CoV-2. ChemMedChem. 2021 11 19; 16(22):3418-3427.
-
Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination. FEBS Lett. 2021 09; 595(18):2366-2382.
-
The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment Turk J Med Sci. 2021 08 30; 51(4):1624-1630.
-
Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. J Infect Public Health. 2021 Sep; 14(9):1247-1253.
-
Alectinib, COVID-19 and favipiravir. J Oncol Pharm Pract. 2021 10; 27(7):1810.
-
Population pharmacokinetics of favipiravir in patients with COVID-19. CPT Pharmacometrics Syst Pharmacol. 2021 10; 10(10):1161-1170.
-
Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021 Dec; 40(12):2575-2583.